Q2 2025 Castle Biosciences Inc Earnings Call Transcript
Key Points
- Castle Biosciences Inc (CSTL) reported strong revenue of $86.2 million for Q2 2025, with a significant year-over-year growth of 33% in core revenue-driving tests.
- The company maintained strong gross margins and ended the quarter with a robust cash position of $275.9 million, enabling continued investment in growth initiatives.
- DecisionDx-Melanoma test showed a 16% sequential increase in test reports compared to Q1 2025, marking the largest second-quarter over first-quarter sequential increase since the company's IPO.
- The company raised its total revenue guidance for 2025 to $310 million to $320 million, up from the previous range of $287 million to $297 million.
- Castle Biosciences Inc (CSTL) is advancing its pipeline with a successful collaboration with SciBase and a promising internally developed test for atopic dermatitis, expected to launch by the end of 2025.
- Net revenues for Q2 2025 decreased by 1% compared to Q2 2024, primarily due to a $12.5 million decrease in revenue from dermatological tests.
- The gross margin for Q2 2025 was 77.3%, down from 80.7% in Q2 2024, with adjusted gross margin also declining.
- DecisionDx-SCC test faced reimbursement challenges, with a noncoverage decision impacting revenue, although a reconsideration request has been submitted.
- Operating expenses increased to $90.4 million in Q2 2025 from $82 million in Q2 2024, driven by higher sales, marketing, and administrative costs.
- Net income for Q2 2025 was $4.5 million, a decrease from $8.9 million in Q2 2024, with diluted earnings per share dropping from $0.31 to $0.15.
Good afternoon, all, and thank you for joining us for the Castle Biosciences' Q2 2025 earnings call. As a reminder, this call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question-and-answer session.
I'd now like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs. Camilla, when you're ready.
Thank you, operator. Good afternoon, everyone. Welcome to Castle Biosciences' second-quarter 2025 results conference call. Joining me today are Castle's Founder, President, and Chief Executive Officer, Derek Maetzold; and Chief Financial Officer, Frank Stokes.
Information recorded on this call speaks only as of today, August 4, 2025. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
